Paradigm Biocapital Advisors LP Edgewise Therapeutics, Inc. Call Options Transaction History
Paradigm Biocapital Advisors LP
- $2.67 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EWTX
# of Institutions
129Shares Held
76.3MCall Options Held
14.7KPut Options Held
14.8K-
Orbimed Advisors LLC San Diego, CA15MShares$276 Million6.17% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$107 Million1.35% of portfolio
-
Black Rock Inc. New York, NY5.17MShares$95 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.02MShares$73.8 Million0.0% of portfolio
-
Viking Global Investors LP3.34MShares$61.4 Million0.23% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.16B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...